5-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2H-pyrazole-3-carboxylic acid | 299936-54-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 英文名称: 5-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2H-pyrazole-3-carboxylic acid
• 英文别名: 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-pyrazole-5-carboxylic acid
• CAS: 299936-54-2
• 化学式: C₁₂H₁₀N₂O₄
• mdl: MFCD02224144
• 分子量: 246.22
• InChiKey: ORKDEZMAVOKLOJ-UHFFFAOYSA-N

物化性质

• 沸点：
  565.9±50.0 °C(Predicted)
• 密度：
  1.468±0.06 g/cm3(Predicted)
• 溶解度：
  32.2 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  84.4
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  1,4-二氮杂双环[3.2.2]壬烷二盐酸盐 、 5-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2H-pyrazole-3-carboxylic acid 生成 4-{[5-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-pyrazol-3-yl]carbonyl}-1,4-diazabicyclo[3.2.2]nonane
  参考文献：
  名称：

  (1,4-Diaza-bicyclo[3.2.2]non-6-en-4-yl)-heterocyclyl-methanone Ligands for Nicotinic Acetylcholine Receptors, Useful for the Treatment of Disease

  摘要：

  本发明一般涉及尼古丁乙酰胆碱受体（nACh受体）配体领域，nACh受体的激活以及与缺陷或功能障碍的尼古丁乙酰胆碱受体相关的疾病状况的治疗，特别是大脑的疾病状况。此外，本发明涉及新型化合物，其作为α7 nACh受体亚型的配体，制备这种化合物的方法，含有这种化合物的组合物以及其使用方法。这些新型化合物包括I式化合物，其中X，R1和R2的定义如本文所述。

  公开号：

  US20100298306A1

文献信息

• LOW AFFINITY SCREENING METHOD
  申请人：Graffinity Pharmaceuticals Aktiengesellschaft

  公开号：EP1360489A1

  公开（公告）日：2003-11-12
• INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF
  申请人：Burnham Institute for Medical Research

  公开号：EP2291372A2

  公开（公告）日：2011-03-09
• Low affinity screening method
  申请人：——

  公开号：US20040082079A1

  公开（公告）日：2004-04-29

  A parallel high throughput screening method on a solid support is disclosed that allows the detection of low affinity binding partners, comprising the steps of:(a) providing a library of different ligands;(b) forming a binding matrix comprising the ligands on a solid support by immobilising said ligands on the support; (c) contacting a target of interest with said binding matrix; (d) parallely determining a binding value of the ligand/target interaction for each type of ligand comprised in the binding matrix; (e) selecting those ligands the binding value of which in an immobilised state towards the target exceeds a predetermined threshold; (f) evaluating the affinity of each of the ligands selected in step (e) in a non-immobilised state towards the target; (g) identifying at least one ligand of step (f) as low affinity binding ligand.
• [EN] LOW AFFINITY SCREENING METHOD<br/>[FR] PROCEDE DE CRIBLAGE DES FAIBLES AFFINITES
  申请人：GRAFFINITY PHARM DESIGN GMBH

  公开号：WO2002063299A1

  公开（公告）日：2002-08-15

  A parallel high throughput screening method on a solid support is disclosed that allows the detection of low affinity binding partners, comprising the steps of:(a) providing a library of different ligands;(b) forming a binding matrix comprising the ligands on a solid support by immobilising said ligands on the support; (c) contacting a target of interest with said binding matrix; (d) parallely determining a binding value of the ligand/target interaction for each type of ligand comprised in the binding matrix; (e) selecting those ligands the binding value of which in an immobilised state towards the target exceeds a predetermined threshold; (f) evaluating the affinity of each of the ligands selected in step (e) in a non-immobilised state towards the target; (g) identifying at least one ligand of step (f) as low affinity binding ligand.
• [EN] INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE LA PHOSPHATASE ALCALINE INTESTINALE ET LEURS UTILISATIONS
  申请人：BURNHAM INST MEDICAL RESEARCH

  公开号：WO2009143150A2

  公开（公告）日：2009-11-26

  Disclosed are modulators, i.e., activators and inhibitors, of Intestinal Alkaline Phosphatase (IAP). Also disclosed are methods for treating bacterial infections of the intestinal tract and methods for maintaining the health of the intestinal tract using IAP activators. Further disclosed are methods to assist in weight gain of emaciated patients and those having reduced or negligible fat absorption using IAP inhibitors.